HOME >> MEDICINE >> NEWS
NCI/Fox Chase Cancer Center Science Writers' Seminar

What: National Cancer Institute (NCI) Science Writers' Seminar Series at Fox Chase Cancer Center, Philadelphia, Pa.

How you or a person you love reacts to the news of a cancer diagnosis can be quite different from how another person would react.

Likewise, those at increased risk of developing cancer face a variety of challenges when communicating that risk to other family members and when making decisions about screening strategies.

Please join us for an in-depth look at decision-making and communication when faced with the threat of cancer. The seminar will provide perspective on how family members react to news of a cancer diagnosis when they themselves may also be at risk due to genetic factors; the two distinct ways in which patients respond to news of cancer; and patients' and doctors' differing expectations about participation in cancer clinical trials

The seminar can also be viewed via live and archived Webcast at http://videocast.nih.gov/.

Who: Robert C. Young, M.D. (Fox Chase) President, Fox Chase Cancer Center; Welcome
Michael Stefanek, Ph.D. (NCI) Integrating basic decision-making into cancer control
Mary Daly, M.D., Ph.D. (Fox Chase) How women communicate genetic test results
Suzanne Miller, Ph.D. (Fox Chase) "Blunters" and "Monitors"; two patient types who process health information very differently
Neal Meropol, M.D. (Fox Chase) Apples and oranges: How patients and doctors think about clinical trials

When: Wednesday, October 5, 2005, from 11 a.m. - 1:30 p.m.

Join us for talks that will begin at 11 a.m., followed by a light lunch served at noon. Additional talks and a Q&A session will conclude by 1:30 p.m.

Where: Fox Chase Cancer Center 333 Cottman Avenue, Philadelphia, Pa. 19111.

Seminar will be held in the Lippincott Room. For directions to Fox Chase, go to

Contact: Dorie Hightower
ncipressofficers@mail.nih.gov
301-496-6641
NIH/National Cancer Institute
29-Sep-2005


Page: 1 2

Related medicine news :

1. Fox Chase study examines which women could benefit from adjuvant therapy with aromatase inhibitor
2. Fox Chase study shows TURP patients with intermediate PSA should be considered high-risk
3. Fox Chase study: Radiation then tamoxifen after lumpectomy for early-stage breast cancer pts
4. American Cancer Society to hold third annual Virtual Relay For Life in Second Life
5. Cancer research summaries
6. Cancer on the agenda of the Portuguese EU Council Presidency
7. Tony Hunter receives Robert. J. and Claire Pasarow Award for Cancer Research
8. OHSU Cancer Institute shows findings of immunotherapy vaccine in prostate cancer patients
9. OHSU Cancer Institute, VA researchers find way to identify which men need a second biopsy
10. OHSU Cancer Institute researcher identifies protein marker for prostate cancer survival
11. Ireland Cancer Center researcher lays out benefits of aspirin to prevent colon cancer

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: NCI Fox Chase Cancer Center Science Writers Seminar

(Date:5/22/2013)... and Los Angeles, CA (PRWEB) May 22, 2013 ... the board, The J. M. Smucker Company, and ... Achievement Awards yesterday at the GS1 General Assembly and ... California. Mr. Smucker and Mr. Wegman were recognized for ... GS1 Standards - the most broadly used supply chain ...
(Date:5/22/2013)... May 22 (HealthDay News) -- Children and teens exposed ... likely to develop cancer, according to a large, long-term ... a group of 10,000 young people who each had ... be expected to occur within 10 years, according to ... doctors should carefully weight the risks to patients when ...
(Date:5/22/2013)... available in German . ... Foundation) is establishing 11 new Research Training Groups to ... was made by the relevant Grants Committee in Bonn. ... to the new programmes for an initial period of ... 11 new Research Training Groups, the Grants Committee approved ...
(Date:5/22/2013)... run, encouraging a baby to finish the last ounce in ... Though the calories soon burn off, a bad habit remains. ... Forste found that clinical obesity at 24 months of age ... overweight at age two, it puts you on a trajectory ... and adolescence and as an adult," said Forste. "That,s a ...
(Date:5/22/2013)... May 22, 2013 The new 13-valent pneumococcal ... the previous version used prior to 2010, the 7-valent ... study published today in Vaccine . , The ... beginning in 2010 after a series of trials. These ... range of pneumococcal types than the previously used PCV7, ...
Breaking Medicine News(10 mins):Health News:Tim Smucker and Danny Wegman Honored With GS1 Lifetime Achievement Awards 2Health News:Tim Smucker and Danny Wegman Honored With GS1 Lifetime Achievement Awards 3Health News:Children Who Have CT Scans May Face Higher Cancer Risk 2Health News:DFG establishes 11 new research training groups 2Health News:DFG establishes 11 new research training groups 3Health News:DFG establishes 11 new research training groups 4Health News:DFG establishes 11 new research training groups 5Health News:Overeating learned in infancy, study suggests 2Health News:Study finds new pneumococcal vaccine appears to be as safe as previously used vaccine 2
(Date:5/22/2013)... -- Cellular Biomedicine Group (OTCQB: CBMG) today announced that it ... enrollment required for its Phase I trial to evaluate the ... Dendritic Cell) therapy for hepatocellular carcinoma (HCC), the most common ... no Severe Adverse Effect (SAE) reported. The Phase ... NIH under number NCT01828762 (click here to view) ...
(Date:5/22/2013)... May 22, 2013 PRNewswire – iBio, ... of a vaccine candidate for the newly emerged ... laboratory using the iBioLaunch™ platform. This validation milestone ... initial antigen sequence information to purification of recombinant ... ) The iBioLaunch platform eliminates the ...
(Date:5/22/2013)... TEL AVIV, Israel , May 22, 2013 /PRNewswire/ ... "Company") (TASE, NASDAQ: EMITF) announced today, further to the ... filed a motion with the Tel Aviv ... of its unsecured creditors and shareholders for the approval ... debt pursuant to a plan of arrangement (the "Arrangement") ...
Breaking Medicine Technology:Cellular Biomedicine Group Announces Enrollment Milestone for Phase I Clinical Trial for Liver Cancer 2Cellular Biomedicine Group Announces Enrollment Milestone for Phase I Clinical Trial for Liver Cancer 3iBio Technology Produces Vaccine Candidate for Recently Emerged H7N9 Influenza 2Elbit Imaging Announces the Court Decision with Respect to Filing of Plan of Arrangement with the Israeli Court 2Elbit Imaging Announces the Court Decision with Respect to Filing of Plan of Arrangement with the Israeli Court 3
Cached News: